Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1998-6-25
|
pubmed:abstractText |
Growing evidence substantiates the role of the insulin-like growth factor I (IGF-1) system in breast tumorigenesis. Retinoids have been shown to affect the IGF system several experimental models. We extended our previous data on plasma IGF-1 modulation by the synthetic retinoid fenretinide (4-HPR) and investigated the effect of the retinoid on plasma IGF binding protein (BP)-3, the major protein binding IGFs. IGF-1 and IGFBP-3 were measured on plasma samples obtained at randomization and after an interval of approximately 1 year, from 39 and 33 stage 1 breast cancer patients assigned to receive 4-HPR, and from 39 and 34 untreated controls, respectively. There was a significant decrease in plasma IGF-1 after 4-HPR administration, whereas no significant change was observed in controls. The effect of 4-HPR on IGF-1 levels was modified by menopausal status, inasmuch as the decrease in IGF-1 was particularly pronounced in pre-menopausal women, whereas the reverse was observed in untreated controls. By contrast, treatment induced an increase of IGFBP-3 with respect to controls. As a result of this dual effect, the bioavailability of IGF-1 for interaction with receptors at target levels further decreased in pre-menopausal 4-HPR treated patients compared with controls, suggesting that retinoid administration may result in lower concentrations of biologically active IGF-1. Our findings may have important implications for the clinical preventive activity of this retinoid.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticarcinogenic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Fenretinide,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor Binding...,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
10
|
pubmed:volume |
76
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
787-90
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:9626341-Adult,
pubmed-meshheading:9626341-Aged,
pubmed-meshheading:9626341-Anticarcinogenic Agents,
pubmed-meshheading:9626341-Breast Neoplasms,
pubmed-meshheading:9626341-Female,
pubmed-meshheading:9626341-Fenretinide,
pubmed-meshheading:9626341-Humans,
pubmed-meshheading:9626341-Insulin-Like Growth Factor Binding Protein 3,
pubmed-meshheading:9626341-Insulin-Like Growth Factor I,
pubmed-meshheading:9626341-Middle Aged
|
pubmed:year |
1998
|
pubmed:articleTitle |
Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.
|
pubmed:affiliation |
Department of Medical Oncology II, National Institute for Cancer Research, Genoa, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|